Keensight Capital Invests in CatSci Ltd

CatSci Acquires Reach Separations

June 25, 2024

Healthcare Services

CatSci Ltd, backed by Keensight Capital, has acquired Reach Separations, a specialist chromatography provider headquartered in the United Kingdom. The deal expands CatSci's CMC and separation science capabilities, enabling end-to-end analytical and purification services from discovery through to manufacture for biotech, pharma and related customers.

Keensight Capital Acquires Inke from Neuraxpharm

May 1, 2023

Pharmaceuticals

Keensight Capital has signed a binding agreement to acquire Inke, a Spain-based specialist developer and manufacturer of inhalation active pharmaceutical ingredients (APIs), from Neuraxpharm Group; financial terms were not disclosed and the deal is expected to close in May 2023. Neuraxpharm divested Inke to sharpen its focus on CNS therapies, while Keensight will support Inke's management team to expand its footprint, broaden its offering and grow its product portfolio.

Keensight Capital Acquires Majority Stake in Axxam

July 28, 2022

Biotechnology

Keensight Capital has agreed to acquire a majority stake in Axxam, an Italian innovative partner research organization (iPRO) headquartered in Milan, investing alongside Axxam's management. The sellers include current shareholders such as Bayer SpA and Zambon Company SpA; Axxam employs around 180 people and reported roughly €30 million of sales in 2021. Keensight intends to support the management team to accelerate growth and further develop Axxam's discovery capabilities.

Keensight Capital Invests in Bedford Consulting

May 10, 2022

IT Services

Keensight Capital has invested a significant stake in Bedford Consulting, the leading EMEA Anaplan implementation partner, alongside Bedford co-founder Neil Doyle and CEO Cathal Doyle. The growth investment will support Bedford's international expansion, deepen its market penetration across Europe, and extend its Anaplan-related service offerings.

Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare

May 25, 2021

Healthcare Services

Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.

Keensight Capital Acquires Majority Stake in Biovian

May 23, 2018

Biotechnology

Keensight Capital has acquired a majority stake in Biovian, a Finnish contract development and manufacturing organization (CDMO) for biopharmaceuticals, alongside the company's founders, managers and Edmond de Rothschild Equity Strategies (ERES) funds. Biovian, founded in 2003 and based in Finland with ~70 employees, provides end-to-end GMP manufacturing, development and analytical services for biologics, gene therapies and vaccines; Keensight will support scaling the business to become a leading European biologics CDMO.